EN DE
Watch UnicoCell Biomed Co., Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

UnicoCell Biomed Co., Ltd. (6794) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of UnicoCell Biomed Co., Ltd. stock TWD 37.17, price TWD 74.20, that is 49.9% below the price, quality 24 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW

UB UnicoCell Biomed Co., Ltd. logo Thin data Nov 16, 2026

UnicoCell Biomed Co., Ltd.

6794 · TW

Far too expensive (fair value 50% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Expensive Growth (revenue 5y +49.9 %/yr in TWD) 
Revenue last quarter 47% below a year ago. 
Fair value 37.17 TWD · Strongly overvalued 
Quality 24/100 
Negative free cash flow 
Trails peers (2/6) 
Narrow moat 9/100
Thin data 
Estimate
Watch UnicoCell Biomed Co., Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

97.00 TWD 31.00 TWD Fair Value 37.17 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 31.00 TWD – 97.00 TWD · fair‑value band 27.88 TWD – 46.46 TWD · the 74.20 TWD price screens above the 37.17 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow UnicoCell Biomed Co. in your weekly email

Every Wednesday you see whether UnicoCell Biomed Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank.

Show moreShow less

In addition, the company offers autologous stem cell therapy; conditioned medium; UnicoVial, a cryogenic vial for the storage of cell products and biological samples under ultra-low temperature; and laboratory testing services, which include sterility, endotoxin, mycoplasma, and cell count and viability tests, as well as contract development and manufacturing organization (CDMO) services for cell-based products.

UnicoCell Biomed Co., Ltd. was founded in 2011 and is based in Taipei, Taiwan.

Stock analysis

UnicoCell Biomed Co., Ltd. (6794) currently trades at 74.20 TWD, while our estimate is 37.17 TWD, 50% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 27.88 TWD (bear) to 46.46 TWD (bull), the price of 74.20 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

UnicoCell Biomed Co., Ltd. reported revenue of 30.1M TWD in FY2025 versus 8.2M TWD in FY2021, a compound +38.5%/yr. Reported net income was −115M TWD in FY2025.

Key figures

Market cap 4.7B TWD (≈ $143M) Micro · EPS (TTM) −1.65 TWD · Return on equity −13.1% · Return on assets (EBIT) −18.5% (5-year average) · Operating margin −631% · Revenue (TTM) 22.5M TWD · Revenue growth (YoY) −47.0% · Free cash flow −96.8M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 19% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −50%, 6794 screens richer than that median.

Fair Value

Bear 27.88 TWD Fair Value 37.17 TWD Bull 46.46 TWD
Price 74.20 TWD · Downside -49.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 24/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 19
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 79
Debt, balance sheet and risk of trouble
Investment 3
Does it invest with discipline instead of growing at any price?
Low Volatility 82
How calm the share price moves, does not count
Price momentum 40
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 39
Distance to the 52-week high, does not count
New shares 29
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−5.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+49.9%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,718.9% (2020) → −432.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6794 screens overvalued: fair value 50% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare UnicoCell Biomed Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 24 · Bottom 25%
Fair Value upside −44.9% · Bottom 25%
Profitability
Return on assets −12.1% · Above median
Growth and dividend
Revenue growth (quarter YoY) −47.0% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.96× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 6794
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 6794
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs 6794
argenx SE ARGX $950.95 $908.40 −4% vs 6794
CSL Limited CSL A$199.55 A$186.49 −7% vs 6794
Moderna, Inc MRNA $215.27 $135.64 −37% vs 6794
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs 6794
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 6794
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs 6794
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 6794

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

UnicoCell Biomed Co., Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "UnicoCell Biomed Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6794

Frequently asked questions

Is UnicoCell Biomed Co., Ltd. (6794) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 37.17 TWD versus a price of 74.20 TWD, about 50% lower (overvalued).
What is the fair value of 6794?
Our estimate for UnicoCell Biomed Co., Ltd. is 37.17 TWD (as of Nov 16, 2026), built from audited fundamentals. The current price: 74.20 TWD.
What is the quality score of 6794?
UnicoCell Biomed Co., Ltd. has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for UnicoCell Biomed Co., Ltd. (6794)?
Our calculated price target is the estimate of 37.17 TWD (as of Nov 16, 2026). Cautious scenario 27.88 TWD, optimistic scenario 46.46 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the UnicoCell Biomed Co., Ltd. stock forecast for 2026?
Our estimate puts fair value at 37.17 TWD, about 50% lower versus a price of 74.20 TWD (overvalued). Cautious scenario 27.88 TWD, optimistic scenario 46.46 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of UnicoCell Biomed Co., Ltd. (6794)?
UnicoCell Biomed Co., Ltd. reported trailing-twelve-month revenue of about 22.5M TWD (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of UnicoCell Biomed Co., Ltd. (6794)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For UnicoCell Biomed Co., Ltd. it is 37.17 TWD per share (as of Nov 16, 2026), against a price of 74.20 TWD.
Is UnicoCell Biomed Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 6794 trades above its calculated fair value: price 74.20 TWD, fair value 37.17 TWD, a gap of about −50% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6794?
No. The price is what the market pays today (74.20 TWD); the fair value is what the company's own numbers justify (37.17 TWD). For UnicoCell Biomed Co., Ltd. the two are 37.03 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is UnicoCell Biomed Co., Ltd. worth?
The market values UnicoCell Biomed Co., Ltd. at about 4.7B TWD (market capitalisation, as of Nov 16, 2026). Per share that is 74.20 TWD; our models calculate a fair value of 37.17 TWD per share.
What do the bullish and bearish scenarios say about 6794?
Our models span a range for UnicoCell Biomed Co., Ltd.: cautious scenario 27.88 TWD, base 37.17 TWD, optimistic 46.46 TWD per share (as of Nov 16, 2026, price 74.20 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of UnicoCell Biomed Co., Ltd. (6794)?
Balance-sheet figures for UnicoCell Biomed Co., Ltd. (as of Nov 16, 2026): return on equity −13.1%. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is 6794 from its 52-week high?
UnicoCell Biomed Co., Ltd. trades at 74.20 TWD, about 19% below its 52-week high of 92.00 TWD and 15% above the low of 64.50 TWD (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 37.17 TWD is for.
Which stocks are comparable to UnicoCell Biomed Co., Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is UnicoCell Biomed Co., Ltd. stock attractive at the current price?
The data as of Nov 16, 2026: price 74.20 TWD, calculated fair value 37.17 TWD (−50%), Quality Score 24/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. UnicoCell Biomed Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of UnicoCell Biomed Co., Ltd. (6794)?
The closing price on Nov 17, 2026 was 74.20 TWD. Our estimate is 37.17 TWD, about 50% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with UnicoCell Biomed Co., Ltd. right now?
The price sits above even our optimistic bull case (46.46 TWD). The favourable scenario is already priced in. Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of UnicoCell Biomed Co., Ltd.

How large is the market capitalisation of UnicoCell Biomed Co., Ltd. (6794)?
The market capitalisation of UnicoCell Biomed Co., Ltd. is 4.7B TWD (≈ $143M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of UnicoCell Biomed Co., Ltd. (6794)?
Earnings per share at UnicoCell Biomed Co., Ltd. are −1.65 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of UnicoCell Biomed Co., Ltd. (6794)?
The return on equity (ROE) of UnicoCell Biomed Co., Ltd. is −13.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of UnicoCell Biomed Co., Ltd. (6794)?
On an EBIT basis the return on assets of UnicoCell Biomed Co., Ltd. is −18.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of UnicoCell Biomed Co., Ltd. (6794)?
The operating margin of UnicoCell Biomed Co., Ltd. is −631% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at UnicoCell Biomed Co., Ltd. (6794)?
Revenue at UnicoCell Biomed Co., Ltd. is down 47.0% versus a year earlier (3y avg +27.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does UnicoCell Biomed Co., Ltd. (6794) generate?
The free cash flow of UnicoCell Biomed Co., Ltd. is −96.8M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does UnicoCell Biomed Co., Ltd. (6794) carry?
The net debt of UnicoCell Biomed Co., Ltd. is 21.0M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch UnicoCell Biomed Co., Ltd. in the live analysis

One click puts UnicoCell Biomed Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.